PJSC Magnitogorsk Iron and Steel Works: MMKnotifies on second extention of consent solicitation process
PJSC Magnitogorsk Iron & Steel Works (MOEX: MAGN; LSE: MMK) notifies on the second extension of the Consent Solicitation for its outstanding U.S.$500,000,000 4.375 per cent. Guaranteed Notes due 2024.
On 9 June 2022, PJSC Magnitogorsk Iron & Steel Works (the “Guarantor ”) announced extension of consent solicitation in relation to the outstanding U.S.$500,000,000 4.375% Notes due 2024 issued by MMK International Capital DAC (the “Issuer ”) (ISIN: XS1843434959 (Regulation S) / US553142AA88 (Rule 144A); Common Code: 111730628 (Regulation S) / 111730628 (Rule 144A Common code)) (the “Notes ”) on the terms and subject to the conditions set forth in the Consent Solicitation Memorandum dated 6 June 2022 (the “Consent Solicitation Memorandum ”). Capitalized terms used, but not defined herein, shall have the meanings given to them in the Consent Solicitation Memorandum.
The Guarantor is pleased to announce that significant progress has been made in obtaining support from investors and thanks those Noteholders, who have already submitted their Consent instructions. In response to requests from a number of accounts requiring additional time in order to pass internal approvals and submit their signatures, the Guarantor announces further extension. The Guarantor thanks all investors who have provided their feedback on the terms of Consent and amendments sought. The Guarantor hereby notifies the Noteholders that it has decided to further extend the Consent Deadline period from 16 June 2022 (4 p.m. (London time)) to 30 June 2022 (4 p.m. (London time)) (the “Updated Consent Deadline ”).
Amendments to the Consent Solicitation are limited to the Updated Consent Deadline, as outlined above. All other terms of the Consent Solicitation will remain the same.
The Guarantor strongly encourages those Noteholders that have not yet participated in the Consent Solicitation to liaise at their earliest convenience with its Investor Relations department and/or Rybalkin, Gortsunyan, Dyakin and Partners Advocates Bureau (“RGD ”) directly to obtain a copy of the Consent Solicitation Memorandum and to discuss other related matters. Noteholders who have already delivered Consent Instructions in the Consent Solicitation will be deemed to have consented to the Amendments unless they validly revoke their Consents prior to the earlier of the Effective time and the Updated Consent Deadline.
All documentation relating to the Consent Solicitation, together with any updates, will be available upon request to RGD at MMKconsentsolicitation2022@rgd.legal . In your communique, please also confirm the aggregate notional amount of the Notes that you hold and the location of the depository.
Noteholders may contact RGD via email at MMKconsentsolicitation2022@rgd.legal if they require assistance.
Should the Noteholders have any additional questions, please contact with the Guarantor’s Investor Relations department via email at: email@example.com.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IL-NIELSENIQ1.7.2022 13:02:08 CEST | Press release
NielsenIQ and GfK to Combine, Creating a Leading Global Provider of Information and Analytics in Consumer and Retail Measurement
FL-VURAM1.7.2022 13:02:08 CEST | Press release
Vuram Names Rhys V Jones As Global Head Of Banking Services
FEELM1.7.2022 10:09:09 CEST | Press release
SMOORE Becomes One of the Shortlisted Enterprises in Shenzhen Municipal Industrial Design Development Support Program
DEXLEVO1.7.2022 09:23:13 CEST | Press release
DEXLEVO Strengthens Global Reputation of GOURI at IMCAS, the World’s Largest Beauty Anti-Aging Society
MA-TAKEDA-PHARMACEUTICAL1.7.2022 00:03:13 CEST | Press release
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom